Baskar S, Wiestner A, Wilson W, Pastan I, Rader C. Targeting malignant B cells with an immunotoxin against ROR1. MAbs. 2012;4:349-61 pubmed publisher

Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012;21:348-61 pubmed publisher

Zhang S, Chen L, Cui B, Chuang H, Yu J, Wang Rodriguez J, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS ONE. 2012;7:e31127 pubmed publisher

Daneshmanesh A, Hojjat Farsangi M, Khan A, Jeddi Tehrani M, Akhondi M, Bayat A, et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia. 2012;26:1348-55 pubmed publisher

Yang J, Baskar S, Kwong K, Kennedy M, Wiestner A, Rader C. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS ONE. 2011;6:e21018 pubmed publisher

Hudecek M, Schmitt T, Baskar S, Lupo Stanghellini M, Nishida T, Yamamoto T, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010;116:4532-41 pubmed publisher

Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro J, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008;105:3047-52 pubmed publisher

Baskar S, Kwong K, Hofer T, Levy J, Kennedy M, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008;14:396-404 pubmed publisher